Most peptides discussed in the biohacking and performance community have one thing in common: their most popular applications have never been tested in humans. TB-500 for tendons. BPC-157 for gut healing. FOXO4-DRI for senolysis. The preclinical data is interesting, the human data is absent, and the community proceeds anyway.
ARA-290 is the opposite situation. It demonstrated actual structural nerve fiber regeneration in a properly controlled human trial. A pre-specified primary endpoint met. A 23% increase in measurable corneal nerve fiber area in 28 days. FDA Fast Track and Orphan Drug designations granted. A successful end-of-Phase 2 FDA meeting completed.
Nobody in the biohacking space is covering it. Part of the reason is that the company that developed it, Araim Pharmaceuticals, has since closed. There is no active Phase 3 program. The evidence exists and is real. The development path forward does not, at least not yet.
That combination: genuinely strong Phase 2 data combined with a stalled development program and no current sponsor: is exactly the kind of nuanced situation that gets flattened in both directions by most peptide content. The hype side ignores the stall. The dismissal side ignores the data. This profile tries to do neither.
ARA-290, also called cibinetide, is a synthetic 11 amino acid peptide derived from the helix-B surface domain of erythropoietin (EPO). EPO is best known as the hormone that stimulates red blood cell production and as a performance-enhancing drug abused in endurance sports. ARA-290 is not EPO. It is a fragment engineered specifically to separate EPO's tissue-protective effects from its hematopoietic effects.
The key distinction is the receptor. EPO stimulates red blood cell production by activating a homodimeric EPO receptor complex. The tissue-protective effects of EPO are mediated by a completely different receptor: a heterodimeric complex composed of the EPO receptor and CD131, the beta-common cytokine receptor. This second receptor is also known as the innate repair receptor (IRR). ARA-290 selectively activates the IRR without touching the hematopoietic receptor complex. The result is tissue protection, anti-inflammation, and nerve repair without any increase in hematocrit, hemoglobin, or clotting risk.
This pharmacological separation is the reason ARA-290 exists. EPO's tissue-protective mechanism is real and compelling, but direct EPO therapy in non-anemic patients carries serious cardiovascular risks. ARA-290 accesses the same downstream biology without those risks.
ARA-290 acts on the innate repair receptor, which is rapidly upregulated locally following tissue injury. Despite a short plasma half-life (approximately 2 minutes after IV administration, approximately 20 minutes after subcutaneous administration, confirmed in a formal crossover pharmacokinetic study by Niesters et al. published in Expert Opinion on Orphan Drugs in 2013), ARA-290 triggers sustained biological effects when concentrations exceed the low nanomolar affinity threshold of the receptor. The peptide acts like a trigger rather than a continuous agent, briefly activating the IRR to initiate a cascade of tissue-protective events that outlast the peptide's presence in circulation.
The downstream effects include reduction in pro-inflammatory cytokines via NF-kB inhibition, protection of mitochondria and cell membranes from oxidative stress, activation of repair pathways in neurons and endothelial cells, and suppression of the NLRP3 inflammasome in Schwann cells during the acute phase of nerve injury.
A second mechanism operates entirely separately from IRR activation: TRPV1 channel antagonism on small nerve fibers. TRPV1 is the receptor involved in mechanical hypersensitivity and neuropathic pain. ARA-290 blocks it directly, addressing pain through a pathway distinct from the repair mechanism. The compound is doing two different things simultaneously: repairing damaged nerve fibers via the IRR, and relieving hypersensitivity via TRPV1 antagonism.
This dual mechanism means ARA-290 is not acting as an analgesic in the conventional sense. It is not masking pain signals. It is reducing the underlying inflammatory pathology that generates them while simultaneously stimulating structural repair of the nerve fibers themselves.
The strongest data for ARA-290 comes from a Phase 2b randomized controlled trial in patients with sarcoidosis-associated small fiber neuropathy, published in Investigative Ophthalmology and Visual Science in 2017 by Culver and colleagues. Sarcoidosis is a systemic inflammatory disease that commonly causes small fiber neuropathy: damage to unmyelinated C-fibers and thinly myelinated A-delta fibers that control pain and autonomic function. Standard anti-inflammatory therapy often fails to restore nerve function.
The trial enrolled 64 participants and was double-blind and placebo-controlled. Patients self-administered cibinetide at 1 mg, 4 mg, or 8 mg daily subcutaneously for 28 days. The pre-specified primary endpoint was change in corneal nerve fiber area (CNFA), measured by corneal confocal microscopy: a non-invasive imaging technique that allows direct visualization of small nerve fibers in the cornea as a surrogate for peripheral small fiber status.
At 28 days, the 4 mg dose produced a placebo-corrected mean increase in corneal nerve fiber area of 697 square micrometers (95% confidence interval: 159 to 1,236; p=0.012). This represents approximately a 23% increase from baseline. The primary endpoint was met at the 4 mg dose. The 1 mg and 8 mg doses did not reach statistical significance for the primary endpoint, indicating a non-linear dose response at the doses studied.
Secondary endpoints confirmed the primary finding through a different biological measure. GAP-43, a marker specifically associated with newly generating axonal growth cones, showed a statistically significant increase in intraepidermal nerve fibers in the 4 mg group (p=0.035). Changes in corneal nerve fiber area correlated significantly with improvements on the 6-minute walk test (rho=0.645, p=0.009), connecting the structural finding to a functional outcome. Pain improvement was also observed in patients with moderate to severe baseline pain in the 4 mg group.
This is not a pain score or a patient-reported outcome. Corneal nerve fiber area measured by confocal microscopy is a measurable structural biological endpoint demonstrating that new nerve fibers were actively growing in response to treatment. The endpoint was pre-specified, the trial was properly controlled, and the primary result was statistically significant at a clinically relevant dose.
Following the Phase 2b result, FDA granted ARA-290 Fast Track designation and Orphan Drug designation for sarcoidosis-associated neuropathy. A successful end-of-Phase 2 meeting with the FDA was completed. These designations and the regulatory meeting reflect recognition of the evidence quality. They do not constitute approval.
A Phase 2 trial published in Molecular Medicine in 2015 by Brines and colleagues enrolled patients with type 2 diabetes and peripheral neuropathy. Participants self-administered 4 mg cibinetide subcutaneously daily for 28 days. The trial reported significant improvements in HbA1c (p=0.002), PainDetect neuropathic symptom score (p=0.03), cholesterol-to-HDL ratio (p=0.039), and triglycerides (p=0.043), alongside an increase in corneal nerve fiber density. The mechanistic rationale is coherent: the same inflammatory pathways ARA-290 targets via the IRR are the pathways driving diabetic nerve damage.
Two research groups investigated ARA-290 in the context of pancreatic islet transplantation. Watanabe and colleagues, published in Transplantation in 2016, showed ARA-290 inhibits macrophage activation and prevents damage to transplanted islets. Yao and colleagues, published in Transplantation in 2020, reported cibinetide improves islet allograft function: in an allogeneic mouse model, cibinetide-treated animals showed allograft survival of 19.3 days versus 1.4 days in controls (p<0.01). EU Orphan Medicinal Product designation was granted for prevention of graft loss in pancreatic islet transplantation.
A Phase 2 trial of cibinetide for diabetic macular edema, published in the Journal of Clinical Medicine in 2020 by Lois and colleagues, enrolled 9 patients who received 4 mg cibinetide subcutaneously daily for 12 weeks. The trial missed its pre-specified primary visual endpoints. Some participants showed improvements in albuminuria as an exploratory finding, suggesting a potential renal microvascular protective signal. The n=9 sample size limits conclusions substantially. This is hypothesis-generating only.
ARA-290 is not sold by research peptide vendors in the same volume as BPC-157 or TB-500. It does not have the cultural footprint of the GH secretagogues. The applications it has the strongest evidence for: sarcoidosis neuropathy and diabetic peripheral neuropathy: are not the performance and longevity applications that drive most community interest.
The result is a compound with Phase 2b human evidence meeting a structural primary endpoint that receives a fraction of the attention given to compounds with no human data at all. BPC-157 has been discussed in the biohacking community for over a decade. It has fewer than 30 humans in published trials across 30 years of research. ARA-290 met a pre-specified structural endpoint in 64 humans in a properly blinded trial and barely registers in community discussion.
The longevity and aging applications of ARA-290 are worth watching specifically because the cardiac aging preclinical data is among the best-designed in this compound class. A 15-month formal randomized controlled trial in aged rats, published in Frontiers in Cardiovascular Medicine in 2023 by Winicki and colleagues, demonstrated reduced cardiac inflammation and attenuated age-associated heart function decline. That is not a standard 4-week mouse study. The beta-common receptor mechanism underlying it is the same receptor already validated in humans for nerve regeneration.
ARA-290 does not have any regulatory approval. The FDA Fast Track and Orphan Drug designations apply to sarcoidosis-associated neuropathy specifically. These designations expedite the review pathway; they are not approvals. No NDA or BLA was ever submitted.
Araim Pharmaceuticals, the company that developed ARA-290 through Phase 2, has closed. No active investigational new drug application exists as of May 2026. No active clinical trials for ARA-290 or cibinetide are registered on ClinicalTrials.gov as of May 2026. Phase 3 would require a new sponsor to initiate an entirely new development program. That has not happened.
This is the critical context that separates honest coverage of ARA-290 from the hype version. The Phase 2b data is real. The structural nerve regeneration finding is real. The FDA designations were real. What is not real is any current path to approval. The stalling of ARA-290's development is attributable to commercial and organizational factors at Araim, not to a scientific failure of the compound itself. The underlying biology remains compelling. The development infrastructure to act on it no longer exists.
The Neisters 2013 PK study confirmed SubQ pharmacokinetics in healthy volunteers and formed the basis for the Phase 2b trial's dosing protocol. Community protocols using subcutaneous injection are therefore not based on unvalidated assumptions about the route. However, the optimal SubQ dosing interval for long-term use outside a clinical trial context has not been formally established.
The longevity, cardiac aging, and stroke applications are entirely preclinical. The cardiac aging data in aged rats is well-designed, but has not been tested in humans. Blood-brain barrier penetration has not been formally characterized in humans.
The 4 mg dose met the primary endpoint in the sarcoidosis trial. The 1 mg and 8 mg doses did not reach statistical significance for the primary endpoint. The optimal dose for indications other than sarcoidosis-associated small fiber neuropathy is not established.
The diabetic macular edema trial missed all of its primary visual endpoints. The albuminuria finding from that trial was exploratory, in 9 patients, and cannot be treated as confirmatory evidence.
ARA-290 is among the most clinically interesting uninvestigated peptides in The Peptide Signal database. It met a structural primary endpoint in a properly controlled human trial: actual measurable nerve fiber regeneration, not a pain score. That is a genuinely differentiated result from what most compounds in this space have ever achieved.
The honest picture in May 2026 is this: the evidence justifying further clinical development is real and has not been refuted. The company that would have run that development no longer exists. No new sponsor has stepped in. The compound sits in a position that is scientifically validated and developmentally orphaned.
If a new sponsor initiates a Phase 3 program, the regulatory pathway is established and the Phase 2b data clearly supports it. If no new sponsor emerges, the sarcoidosis neuropathy population: a group with no approved disease-modifying therapy: continues to lack an option that Phase 2 data suggests could help them. That gap is worth tracking.
Culver DA, et al. (2017). Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain. Investigative Ophthalmology and Visual Science.
Brines M, et al. (2015). ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine.
Dahan A, et al. (2013). ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Molecular Medicine.
Niesters M, et al. (2013). The erythropoietin analog ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain. Expert Opinion on Orphan Drugs. Includes crossover pharmacokinetic study comparing IV and subcutaneous administration in healthy volunteers.
Watanabe M, et al. (2016). A nonhematopoietic erythropoietin analogue, ARA 290, inhibits macrophage activation and prevents damage to transplanted islets. Transplantation.
Yao M, et al. (2020). Improvement of islet allograft function using cibinetide, an innate repair receptor ligand. Transplantation.
Lois N, et al. (2020). A Phase 2 clinical trial on the use of cibinetide for the treatment of diabetic macular edema. Journal of Clinical Medicine.
Winicki N, et al. (2023). A small EPO-derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age-associated declines in heart function, and prolongs healthspan. Frontiers in Cardiovascular Medicine.
Brines M, et al. (2008). Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proceedings of the National Academy of Sciences.
Swartjes M, et al. (2011). ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Anesthesiology.
Development status note: Araim Pharmaceuticals, the company that developed ARA-290 through Phase 2, has closed. No active IND, NDA, or registered clinical trial exists for ARA-290 as of May 2026. Verified via ClinicalTrials.gov and multiple current sources. May 2026.
Every Tuesday: one landmark study, one protocol, one regulatory update. Plus new research posts as they publish. Free.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use